Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)

NCT00386685 Phase 2 COMPLETED

The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab. The secondary objectives are safety and pharmacokinetic interaction

Details

Lead sponsor	Sanofi
Phase	Phase 2
Status	COMPLETED
Enrolment	51
Start date	2006-07
Completion	2011-01

Conditions

• Breast Neoplasms

Interventions

• larotaxel (XRP9881)
• trastuzumab

Primary outcomes

• Response rate (best overall response under treatment) — study period

Countries

Belgium, France, Sweden, Switzerland